NTLA Stock Recent News

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) BofA Securities 2025 Healthcare Conference May 13, 2025 7:20 PM ET Company Participants Ed Dulac - CFO Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Hello, everyone. Thanks for joining the session with Intellia Therapeutics on day 1 of the 2025 Bank of America Healthcare Conference.

Investors who've been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test results that were fine with medical experts and the FDA. The Street hated when NTLA dropped a lesser program and laid off some staff members. On 5/8/25, the Company reported further progress with two treatments that are now ensconced in Phase III of testing—a level only a third of new drugs reach.

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates.

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Brittany Chaves - Senior Manager of Investor Relations John Leonard - President and Chief Executive Officer David Lebwohl - Chief Medical Officer Ed Dulac - Executive Vice President and Chief Financial Officer Birgit Schultes - Executive Vice President and Chief Scientific Officer Conference Call Participants Gena Wang - Barclays Kostas Biliouris - BMO Capital Markets Luca Issi - RBC Maury Raycroft - Jefferies Mitchell Kapoor - H. C. Wainwright Jay Olson - Oppenheimer Rick Bienkowski - Cantor Fitzgerald Yanan Zhu - Wells Fargo Troy Langford - TD Cowen Jake Roberge - William Blair Brian Cheng - JPMorgan William Pickering - Bernstein David Lebowitz - Citi Operator Good morning, and welcome to Intellia' First Quarter 2025 Financial Results Conference Call.

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.06 per share a year ago.

CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an inducement grant to eight new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better positioned to navigate near-term challenges with a strong cash reserve and upcoming product launches, justifying an upgrade to 'Strong Buy.' NTLA, despite promising product candidates, faces higher risks and requires significant cost reductions to extend its cash runway, maintaining a "Buy" rating for high-risk investors.

Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NTLA broke out above the 50-day moving average, suggesting a short-term bullish trend.

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET.